Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Tryptamine...
Vous n'êtes pas connecté
SYDNEY, July 10, 2024. Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients...
Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Tryptamine...
Glioblastoma multiforme (GBM) stands as a formidable adversary in oncology, characterized by its molecular complexity and relentless progression.
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based...
In this episode, host Sarah Hughan tells all on Tryptamine Therapeutics' (ASX:TYP) recent trial showing pain reduction in every patient. ...
Health consequences of over active xanthine oxidase may accelerated PKD progression CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) — XORTX...
Tryptamine Therapeutics' (ASX:TYP) Jason Carroll joins Sarah Hughan on Stockhead TV to talk about its drug trial to treat fibromyalgia. ...
Highlights: Tirzepatide significantly lowers hospitalization and death risks in heart failure patients The drug
Indian Council of Medical Research (ICMR) and Panacea Biotec declared the start of Phase III clinical trial for India's first dengue vaccine.
TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and...
Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study...